Categories
Weight Loss Products

Square: 51 Pct Of GPV Comes From Larger Sellers

Square‘s Q4 earnings 2018 results came after market close on Wednesday (Feb. 27), showing the continuation of several trends seen in recent quarterly reports. These trends included double-digit gross payment volume (GPV) growth, as measured year on year, double-digit transaction gains and traction in newer technology offerings — such as point-of-sale (POS) financing to help sellers log their own top-line growth.

In terms of headline numbers, the payments processing firm reported adjusted revenues of $464 million, up 64 percent year on year, while the Street had looked for $454 million. Earnings on an adjusted basis were $0.14 per share, which matched the Street.

Gross Payment Volume And Large Seller Mix Growth 

Digging into the numbers a bit, GPV was up 28 percent in Q4 to $23 billion. Transaction-based revenue was up 27 percent to $668 million. The Cash App, Square said, had more than 15 million monthly active users in December 2018, more than double the number seen in the final month of 2017.

In terms of seller mix, those with annualized volumes north of $500,000 were 24 percent of the GPV, while those between $125,000 and $500,000 were 28 percent. That means larger sellers made up 51 percent of the mix, compared to a similar tally of 47 percent in the same period last year. (Management also spotlighted the fact that verticals such as restaurants are seeing increased momentum with Square’s offerings.)

With more granular detail on mix and technology adoption, newly joined Square CFO Amrita Ahuja said during the conference call with analysts that 30 percent of those sellers serve customers across more than one channel on Square. She added that Virtual Terminal, Invoices and eCommerce API offered up more than 10 percent of the company’s GPI in Q4.

Square also said its recently launched Payroll offering has been useful in helping sellers manage operations, as smaller firms may be relatively underserved by traditional payroll providers. As much as one-third of firms that signed on to Square Payroll throughout 2018 were new to the company, according to supplemental materials filed by Square with its earnings announcement.

In Q4, Square Capital facilitated 72,000 business loans at $472 million, up 55 percent year on year.

In reference to questions about installment payment options (where payment plans can be set up for purchases ranging from $250 to $10,000), introduced during the final months of 2018, CEO Jack Dorsey noted the introduction is still “early,” but that the offering gives Square’s sellers a “tool” that can help compel customers to make a purchase.

Hardware revenue in Q4 was $18 million, up 51 percent year on year, and driven by Square Terminal, Square Register and third-party peripherals. All this leads to — as Dorsey said on the call — an “ecosystem” for the company’s sellers and customers.

In his comments on the Square Card, a free business debit card that allows sellers to access funds upon logging sales, Dorsey said the firm has identified a “pain point” that can be addressed by linking accounts and helping owners invest in their businesses. Square estimated that as much as 40 percent of Square Card beta sellers (per research conducted last month) did not previously have a business debit card. He noted that the card enables new businesses to launch without the need for traditional banking in place, which he termed “pretty profound.” Elsewhere on the call, he said the card can help underserved, underbanked sellers.

Ahuja and Dorsey also explained on the call how there had been a “network effect” that helped the company see growth in products and services that were announced and launched within the last five years. Moving forward, management said that focus would remain on mobile payments and online initiatives.

In after-hours trading, Square shares fell as much as 6 percent, as guidance on an adjusted basis of between $0.06 to $0.08 per share missed the Street estimate of $0.11. Square said it will continue to invest in growth.

——————————–

Latest Insights: 

Our data and analytics team has developed a number of creative methodologies and frameworks that measure and benchmark the innovation that’s reshaping the payments and commerce ecosystem. Check out our February 2019 Payments And The Platform Economy Report 

, , , , , , , , , , , , ,

Recommended for you

Categories
Weight Loss Products

What’s NUTRAFUELS INC (OTCMKTS:NTFU) Upside After This Short Interest Increase? | Thorold News

The stock of NUTRAFUELS INC (OTCMKTS:NTFU) registered an increase of 192% in short interest. NTFU’s total short interest was 14,600 shares in March as published by FINRA. Its up 192% from 5,000 shares, reported previously. With 100,800 shares average volume, it will take short sellers 0 days to cover their NTFU’s short positions.

The stock increased 0.20% or $0.0004 during the last trading session, reaching $0.1743. About 27,175 shares traded. NutraLife BioSciences, Inc. (OTCMKTS:NTFU) has 0.00% since March 10, 2018 and is . It has underperformed by 4.37% the SP500.

NutraFuels, Inc. manufactures and distributes oral spray nutritional and dietary products to retail and wholesale outlets. The company has market cap of $19.17 million. The companyÂ’s products include sleep spray to support a healthy sleep cycle and improve the quality of restful sleep; energize spray to enhance energy, and restore vigor and vitality; and garcinia cambogia spray, an appetite and weight management spray. It currently has negative earnings. It also offers NRG-X extreme energy spray to enhance energy and stamina; headache and pain spray to relieve headaches and pain; and hair, skin, and nails spray to nourish and encourage hair, skin, and nail growth.

More news for NutraLife BioSciences, Inc. (OTCMKTS:NTFU) were recently published by: Marketwired.com, which released: “NutraFuels (NTFU) Files its Application to Up List to the OTCQB OTC Market – Marketwired” on January 29, 2018. Globenewswire.com‘s article titled: “Freedom Leaf Inc. Announces National Distribution Agreement Other OTC:FRLF – GlobeNewswire” and published on February 28, 2018 is yet another important article.

Receive News Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


Categories
Weight Loss Exercise

Which Has Better Health Effects THC or CBD in Marijuana?

In a recent study titled “The Association between Cannabis Product Characteristics and Symptom Relief,” published in the journal Scientific Reports, UNM researchers Sarah See Stith, assistant professor in the Department of Economics, and Jacob Miguel Vigil, associate professor in the Department of Psychology, found that THC and CBD contents were the most important factor for optimizing symptom relief for a wide variety of health conditions.

Cannabis is rapidly gaining popularity as a mid-level analgesic and promising substitute for prescription opioids and other classes of medications, which often carry undesirable side effects, dangerous drug interactions and risk of death. Presently, federal barriers restrict researchers from conducting cannabis administration studies in the U.S.

One of the real shockers, to me anyway was the finding that THC has more health benefits than CBD.

Which Has Better Health Effects THC or CBD in Marijuana?

I have done some research (no, not smoking it), and CBD has always seemed like the compound in marijuana that had health benefits while the THC in Marijuana just got people high. I was not alone in that thinking .

Jacob Miguel Vigil, one of the researchers, and a well published author of papers as well had this to say

Despite the conventional wisdom, both in the popular press and much of the scientific community that only CBD has medical benefits while THC merely makes one high, our results suggest that THC may be more important than CBD in generating therapeutic benefits. In our study, CBD appears to have little effect at all, while THC generates measurable improvements in symptom relief. These findings justify the immediate de-scheduling of all types of cannabis, in addition to hemp, so that cannabis with THC can be more widely accessible for pharmaceutical use by the general public.

Here in Canada we see lots of news on Marijuana health benefits since the legalization of Cannabis last November. I am sure that studies like this will be interesting in the public conversation as most people would not want to admit that there is any health advantages to getting high even while CBD oil is a non psychoactive compound that people and doctors are recommending for stress relief as well as treating of mental illnesses